Translational Development Acquisition Corp. (TDAC)
TDAC 8-K filings, explained
Every material Form 8-K Translational Development Acquisition Corp. has filed with the SEC since June 23, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Translational Development Acquisition Corp. (TDAC) entered a subscription agreement under which Naetas Holding Limited will buy 5,000,000 TDAC Class A ordinary shares at $10.00 each, for $50,000,000, and receive 5,000,000 warrants at no additional consideration. The purchase is tied to the closing of TDAC's business combination with ProLogium Holding Inc., and the closing is contingent on that combination being completed, so shareholders would see new shares and warrants issued only if the merger proceeds.
Subscriber: Naetas Holding Limited, an institutional accredited investor, purchasing 5,000,000 Class A ordinary shares at $10.00 per share for $50,000,000
Subscribed Warrants: 5,000,000, exercisable at $11.50 per share, with a $18.00 redemption trigger and $0.01 redemption price
Closing expected one business day before the first merger; the subscription terminates if the Business Combination Agreement is validly terminated or the Termination Date passes without closing
ProLogium to file a resale registration statement within 45 calendar days after the Business Combination closes, after the Form F-4 is declared effective
Translational Development Acquisition Corp. (TDAC) said ProLogium Holding Inc. has filed a Form F-4 registration statement with the SEC, a step in the business combination announced on May 27, 2026. The filing is subject to SEC review and may be revised, and the release does not state a closing date or new deal terms.
ProLogium filed its initial Form F-4 with the SEC, as announced in a press release dated July 6, 2026.
The merger transaction was announced on May 27, 2026.
The filing is subject to SEC review and may be revised.
The forward-looking statements cite a $250 million Minimum Cash condition to closing.
Translational Development Acquisition Corp. (TDAC) reported the results of redemptions tied to its June 17, 2026 shareholder vote on extending its deadline to complete an initial business combination. Public shareholders redeemed 2,598,697 Class A shares, and holders of 14,651,303 shares chose to keep them, leaving about $156.8 million in the trust account. The vote concerns TDAC's proposed business combination with ProLogium Holding Inc.
Public shareholders redeemed 2,598,697 Class A shares; holders of 14,651,303 shares continued to hold them.
About $156.8 million remains in the trust account after redemptions.
The press release states that 95% of the shares voted were in favor of the extension.
TDAC announced a merger agreement with ProLogium on May 27, 2026; the filing cites a $250 million Minimum Cash condition to closing.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Translational Development Acquisition Corp. filing is on SEC EDGAR ↗. 8-K briefs of other companies →